AnaptysBio Announces Second Quarter 2023 Financial Results&#

07.08.2023 - Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid ...

Related Keywords

Bristol Meyers Squibb , Daniel Faga , Luisa Salter Cid , Nick Montemarano , Dolca Thomas , Jamie Topper , Dan Faga , Anaptysbio Inc , Strategic Communications , Exchange Commission , Company Scientific Advisory Board , Company Board Of Directors , Federation Of Clinical Immunology Societies , Wholly Owned Immune Cell Modulator , Clinical Immunology Societies , Annual Meeting , Investigational New Drug , Oncology Financial , Scientific Advisory Board , Pioneering Medicines , Samsara Biocapital , Allakos Therapeutics , Chinook Therapeutics , Translational Medicine , Infectious Disease , Private Securities Litigation Reform Act , Investor Relations , Anaptysbio ,